Stay updated on Avutometinib Combo in KRAS G12C NSCLC Clinical Trial

Sign up to get notified when there's something new on the Avutometinib Combo in KRAS G12C NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Avutometinib Combo in KRAS G12C NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T23:19:42.000Z thumbnail image
  5. Check
    29 days ago
    No Change Detected
  6. Check
    36 days ago
    Change Detected
    Summary
    The webpage now includes a notice about heavy traffic affecting NLM-NCBI services and provides updated contact information for assistance. Additionally, several past dates and an email address have been removed.
    Difference
    2%
    Check dated 2025-02-10T17:14:43.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T11:59:26.000Z thumbnail image
  8. Check
    58 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-20T04:16:03.000Z thumbnail image
  9. Check
    65 days ago
    Change Detected
    Summary
    The website has updated its list of principal investigators and their contact information, removing the previous designation of 'Principal Investigator' from each entry while retaining the names and phone numbers.
    Difference
    28%
    Check dated 2025-01-12T23:36:09.000Z thumbnail image
  10. Check
    79 days ago
    Change Detected
    Summary
    New criteria for inclusion in clinical trial cohorts have been added, specifying exposure to KRAS inhibitors for Part A and Part B, while previous criteria have been removed.
    Difference
    1%
    Check dated 2024-12-29T16:11:06.000Z thumbnail image

Stay in the know with updates to Avutometinib Combo in KRAS G12C NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Avutometinib Combo in KRAS G12C NSCLC Clinical Trial page.